SCHEMBL22025030

SCHEMBL22025030

Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1Nc1nc(-c2cccc(N)c2)nc2c1cnn2C

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 7/20 0.81
EPHB2 P29323 3/20 0.81
DDR1 Q08345 3/20 0.81
DDR2 Q16832 3/20 0.81
BTK Q06187 3/20 0.81
LCK P06239 3/20 0.81
SRC P12931 3/20 0.81
MAPK14 Q16539 3/20 0.81
ESYT2 A0FGR8 2/20 0.81
NBAS A2RRP1 2/20 0.81
CNOT1 A5YKK6 2/20 0.81
TBKBP1 A7MCY6 2/20 0.81
AGPS O00116 2/20 0.81
MYO1F O00160 2/20 0.81
SNAP23 O00161 2/20 0.81
AP3B1 O00203 2/20 0.81
PSMD12 O00232 2/20 0.81
BMPR1B O00238 2/20 0.81
PGRMC1 O00264 2/20 0.81
CLIC1 O00299 2/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22025313 0.93 BRAF (0.80) BRAFEPHB2DDR1DDR2BTK
SCHEMBL22024695 0.92 BRAF (0.86) BRAFEPHB2DDR1DDR2BTK
SCHEMBL22025026 0.92 BRAF (0.82) BRAFEPHB2DDR1DDR2BTK
SCHEMBL22024561 0.91 BRAF (0.81) BRAFEPHB2DDR1DDR2BTK
SCHEMBL29358745 0.90 ABL1 (1.00) BRAFEPHB2DDR1DDR2BTK
SCHEMBL4699731 0.90 ABL1 (1.00) BRAFEPHB2DDR1DDR2BTK
SCHEMBL29380618 0.90 ABL1 (1.00) BRAFEPHB2DDR1DDR2BTK
SCHEMBL23092285 0.89 BRAF (0.86) BRAFEPHB2DDR1DDR2BTK
SCHEMBL22024567 0.89 BRAF (0.81) BRAFEPHB2DDR1DDR2BTK
SCHEMBL29688472 0.89 BRAF (0.86) BRAFEPHB2DDR1DDR2BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352354-B2 Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof XIAMEN UNIVERSITY (CN) 2022-06-07 US disclosed
EP-3663293-A1 SUBSTITUTED PENTA- AND HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF Xiamen University (CN) 2020-06-10 EP disclosed
US-20200165246-A1 SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF XIAMEN UNIVERSITY (CN) 2020-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352354-B2 Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof PIKFYVE, PIK3CA, PIK3C2A BRAF 65/4885EPHB2 4397/4885DDR1 1422/4885
US-20200165246-A1 SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF PIKFYVE, PIK3CA, PIK3C2A BRAF 65/4885EPHB2 4397/4885DDR1 1422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.